Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 5NIH 3INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Stomatitis 9Neoplasms 6Head and Neck Neoplasms 4Multiple Myeloma 2Mucositis 2Leukemia 2Xerostomia 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Oral Ulcer 1Lymphoma, Non-Hodgkin 1Lymphoma 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Laryngeal Diseases 1Hematologic Neoplasms 1Graft vs Host Disease 1Deglutition Disorders 1Colonic Neoplasms 1Cataract 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Rituximab 63Cyclophosphamide 37Brentuximab Vedotin 22Bendamustine Hydrochloride 22pembrolizumab 20fludarabine 20Gemcitabine 20Doxorubicin 20Prednisone 19ibrutinib 17Vincristine 16obinutuzumab 14Lenalidomide 13Nivolumab 10Rifampin 8parsaclisib 7duvelisib 7atezolizumab 7Vorinostat 7Dexamethasone 7Azacitidine 7spartalizumab 6loncastuximab tesirine 6MLN 8237 6venetoclax 5ixazomib 5glofitamab 5fludarabine phosphate 5durvalumab 5acalabrutinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoma × Fibroblast Growth Factor 7 × Clear all
NCT00109031 2014-09-15

Palifermin for the Reduction of Oral Mucositis in Single-dose Evaluation (PROMISE)

Swedish Orphan Biovitrum

Phase 3 Completed
47 enrolled 19 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡